drugset / Trial / NCT05113849
Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)
Non-randomizedSequentialOpen-labelPrevention
Summary
This is a first in human, phase I, open-label, dose-escalation study to assess the safety, reactogenicity, and immunogenicity of a SARS-CoV-2 Vaccine (IN-B009) in healthy adults.
Timeline
- Start
- 2021-09-16
- Primary completion
- 2023-02
- Completion
- 2023-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IN-B009 | Vaccine | — | Intramuscular |